Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Wnt-1 CRISPR/Cas9 KO Plasmid (h): sc-400982
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Wnt-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Wnt-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Wnt-1 Antibody (E-10): sc-514531
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Wnt-1 CRISPR/Cas9 KO Plasmid (h) | sc-400982 | 20 µg | $397.00 |
Overview
WNT1 encodes Wnt-1, a secreted glycoprotein that functions as a morphogen and ligand for Frizzled/LRP receptors to activate canonical Wnt/β-catenin signaling. Through regulation of β-catenin stabilization and TCF/LEF-dependent transcription, Wnt-1 influences cell fate specification, proliferation, and differentiation during development and tissue homeostasis. WNT1 activity interfaces with pathways controlling epithelial organization and progenitor cell programs, and dysregulation of Wnt signaling is broadly implicated in oncogenic transformation and aberrant growth control. Variants in WNT1 have also been associated with skeletal biology and bone formation phenotypes, supporting its relevance to developmental and regenerative research.
Wnt-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the WNT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the WNT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the WNT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Wnt-1 protein expression.
This CRISPR knockout system enables efficient generation of WNT1-deficient cell models for investigation of Wnt-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting WNT1 exon(s) critical for Wnt-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple WNT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Wnt-1 CRISPR/Cas9 KO Plasmid (h) and Wnt-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the WNT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Wnt-1 HDR Plasmid (h) and Wnt-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by WNT1 homology arms to support homology-directed repair at defined WNT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.